Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease

Effect of Nicotine on the Pharmacokinetics of Levodopa

(2013) Win Thiri Kyaw et al.   CLINICAL NEUROPHARMACOLOGY

Emerging therapies for Parkinsonʼs disease

(2012) Werner Poewe et al.   CURRENT OPINION IN NEUROLOGY

Nicotine as a potential neuroprotective agent for Parkinson's disease

(2012) Maryka Quik et al.   MOVEMENT DISORDERS

Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function

(2012) Maryka Quik et al.   NEUROBIOLOGY OF DISEASE

Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+

(2011) Damien Toulorge et al.   FASEB JOURNAL

Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation

(2011) Mahmoud M. Iravani et al.   JOURNAL OF NEURAL TRANSMISSION

Nicotine Reduces L-DOPA-Induced Dyskinesias by Acting at  2* Nicotinic Receptors

(2011) L. Z. Huang et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Milestones in Parkinson's disease therapeutics

(2011) Olivier Rascol et al.   MOVEMENT DISORDERS

Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats

(2011) Luping Z. Huang et al.   NEUROPHARMACOLOGY

Nicotine Alters Limbic Function in Adolescent Rat by a 5-HT1A Receptor Mechanism

(2011) Jasmin M Dao et al.   NEUROPSYCHOPHARMACOLOGY

Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia

(2011) M. Carta et al.   NEUROSCIENCE

 6 2* and  4 2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson's Disease

(2011) M. Quik et al.   PHARMACOLOGICAL REVIEWS

Nicotinic Receptor-Mediated Reduction in L-DOPA-Induced Dyskinesias May Occur via Desensitization

(2010) T. Bordia et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Differential effects of serotonin (5-HT)2receptor-targeting ligands on locomotor responses to nicotine-repeated treatment

(2010) Magdalena Zaniewska et al.   SYNAPSE

Structural and functional diversity of native brain neuronal nicotinic receptors

(2009) Cecilia Gotti et al.   BIOCHEMICAL PHARMACOLOGY

Nicotinic Receptor-Mediated Neuroprotection in Neurodegenerative Disease Models

(2009) Shun Shimohama   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Interactions of serotonin (5-HT)2receptor-targeting ligands and nicotine: Locomotor activity studies in rats

(2009) Magdalena Zaniewska et al.   SYNAPSE

Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats

(2008) Edward D. Levin et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Continuous and Intermittent Nicotine Treatment Reduces L-3,4-Dihydroxyphenylalanine (L-DOPA)-Induced Dyskinesias in a Rat Model of Parkinson's Disease

(2008) T. Bordia et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Nicotine and Parkinson's disease: Implications for therapy

(2008) Maryka Quik et al.   MOVEMENT DISORDERS

Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: Potential targets for the development of new therapeutic agents

(2008) Roberta J. Ward et al.   PROGRESS IN NEUROBIOLOGY

Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease

(2007) Marina et al.   Frontiers in Bioscience-Landmark